218 related articles for article (PubMed ID: 12038784)
1. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
McCarthy K; Stewart P; Sigman J; Read M; Keith JC; Brinkhous KM; Nichols TC; Schaub RG
Thromb Haemost; 2002 May; 87(5):824-30. PubMed ID: 12038784
[TBL] [Abstract][Full Text] [Related]
2. Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.
Russell KE; Read MS; Bellinger DA; Leitermann K; Rup BJ; McCarthy KP; Keith JC; Khor SP; Schaub RG; Nichols TC
Thromb Haemost; 2001 Mar; 85(3):445-9. PubMed ID: 11307812
[TBL] [Abstract][Full Text] [Related]
3. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
[TBL] [Abstract][Full Text] [Related]
5. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
[TBL] [Abstract][Full Text] [Related]
6. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
[TBL] [Abstract][Full Text] [Related]
7. Prolonged activity of factor IX as a monomeric Fc fusion protein.
Peters RT; Low SC; Kamphaus GD; Dumont JA; Amari JV; Lu Q; Zarbis-Papastoitsis G; Reidy TJ; Merricks EP; Nichols TC; Bitonti AJ
Blood; 2010 Mar; 115(10):2057-64. PubMed ID: 20056791
[TBL] [Abstract][Full Text] [Related]
8. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
Preijers T; Hazendonk HCAM; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA
J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
Chang HH; Yang YL; Hung MH; Tsay W; Shen MC
J Formos Med Assoc; 2007 Apr; 106(4):281-7. PubMed ID: 17475604
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog.
Keith JC; Ferranti TJ; Misra B; Frederick T; Rup B; McCarthy K; Faulkner R; Bush L; Schaub RG
Thromb Haemost; 1995 Jan; 73(1):101-5. PubMed ID: 7740479
[TBL] [Abstract][Full Text] [Related]
11. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa.
Nichols TC; Levy H; Merricks EP; Raymer RA; Lee ML
PLoS One; 2020; 15(10):e0240896. PubMed ID: 33112889
[TBL] [Abstract][Full Text] [Related]
13. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.
Russell KE; Olsen EH; Raymer RA; Merricks EP; Bellinger DA; Read MS; Rup BJ; Keith JC; McCarthy KP; Schaub RG; Nichols TC
Blood; 2003 Dec; 102(13):4393-8. PubMed ID: 12933577
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies of recombinant factor IX.
Schaub R; Garzone P; Bouchard P; Rup B; Keith J; Brinkhous K; Larsen G
Semin Hematol; 1998 Apr; 35(2 Suppl 2):28-32. PubMed ID: 9565164
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of recombinant factor IX.
White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
[TBL] [Abstract][Full Text] [Related]
16. [Successful management of neurosurgical procedures with continuous infusion of recombinant factor IX in a child with hemophilia B].
Yamamoto M; Nakadate H; Iguchi U; Masuda H; Sakai H; Ishiguro A
Rinsho Ketsueki; 2013 Mar; 54(3):300-4. PubMed ID: 23676647
[TBL] [Abstract][Full Text] [Related]
17. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
Nummi V; Jouppila A; Lassila R
Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
Alamelu J; Bevan D; Sorensen B; Rangarajan S
J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
[TBL] [Abstract][Full Text] [Related]
20. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
